+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugate Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 118 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5707273
Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. By attaching biologically active chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers with liable bonds to a monoclonal antibody directed to antigens differentially overexpressed in tumor cells, ADCs significantly improve sensitive discrimination between healthy and diseased tissue.

The report titled Global Antibody Drug Conjugate Market- Growth, Future Prospects and Competitive Analysis, 2022 - 2030 offers strategic insights into the overall Antibody Drug Conjugate market along with the market size and estimates for the duration 2022 to 2030. The research study covers in-depth analysis of market segments based on drug type and different geographical region.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global Antibody Drug Conjugate market. Pipeline analysis of the drugs currently in the clinical trial stage is also included in the report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global Antibody Drug Conjugate market. This report concludes with company profiles section that highlights major information about the key players engaged in global Antibody Drug Conjugate market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global Antibody Drug Conjugate market, offering market size and estimates for the period from 2022 to 2030, keeping in mind the above-mentioned factors.

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. By attaching biologically active chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers with liable bonds to a monoclonal antibody directed to antigens differentially overexpressed in tumor cells, ADCs significantly improve sensitive discrimination between healthy and diseased tissue. Currently marketed drugs suffers from various stipulations like low potency, lack of specificity and adverse effects. This has forced the pharmaceutical and research companies to develop therapeutics that can overcome these barriers. Commercializing antibody drug conjugates have overcome these scenarios and improve the medical conditions. The currently marketed antibody drug conjugate drugs are Adcetris (Seattle Genetics) and Kadcyla (Genentech/Roche). Additionally there are more than 50 molecules in the pre-clinical stage. Out of these, approximately 25% are in Phase II or Phase III of development, leading to a rapidly expanding pre-clinical pipeline. With more than 190 active clinical trials, antibody-drug conjugates are gaining acceptance across the globe as they offer superior pharmacological efficiency along with minimized side effects.

The geographical segmentation of the global antibody drug conjugate market comprises North America, Europe, Asia-Pacific, and Rest of the World. In base year 2021, North America accounted for the largest market in the antibody drug conjugate market due to the presence of major pharmaceutical companies working on the development of antibody drug conjugate drugs. Moreover, one of the prime reason of North America’s dominance in the antibody drug conjugates market is the fast-track approval and commercialization of ADCs in the region as compared to other geographical regions. Europe held the second largest market for antibody drug conjugates market. Kadcyla, one of the two drugs that are marketed currently is manufactured by the Europe based pharmaceutical giant, Roche. Additionally, Europe was the second region after where the commercialization of the ADCs were approved on a fast-track basis. There are more 190+ clinical trials currently being carried on in Europe and North America. Asia pacific is anticipated to be the fastest growing segment in the antibody drug conjugate market due to the approval of ADCs in Japan, China. Kadcyla was approved and launched in the India market as premium priced drug in 2020. Fast-track approvals of breakthrough drugs in Asia-Pacific would further drive the antibody drug conjugate market during the forecast period.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Antibody Drug Conjugate market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Antibody Drug Conjugate market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

  • Kadcyla
  • Adcetris
  • Pipeline Analysis of Antibody Drug Conjugate

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Antibody Drug Conjugate market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Antibody Drug Conjugate market?
  • Which is the largest regional market for Antibody Drug Conjugate market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Antibody Drug Conjugate market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Antibody Drug Conjugate market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Antibody Drug Conjugate Market
2.2. Global Antibody Drug Conjugate Market, By Drug, 2021 (US$ Million)
2.3. Global Antibody Drug Conjugate Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Antibody Drug Conjugate Market: Competitive Analysis
3.1. Market Positioning of Key Antibody Drug Conjugate Market Vendors
3.2. Strategies Adopted by Antibody Drug Conjugate Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Antibody Drug Conjugate Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Antibody Drug Conjugate Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Kadcyla
5.3.2. Adcetris
5.3.3. Pipeline Analysis of Antibody Drug Conjugate
6. North America Antibody Drug Conjugate Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
6.3.Antibody Drug Conjugate Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
7. UK and European Union Antibody Drug Conjugate Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
7.3.Antibody Drug Conjugate Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
8. Asia Pacific Antibody Drug Conjugate Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
8.3.Antibody Drug Conjugate Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
9. Latin America Antibody Drug Conjugate Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
9.3.Antibody Drug Conjugate Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
10. Middle East and Africa Antibody Drug Conjugate Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
10.3.Antibody Drug Conjugate Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Antibody Drug Conjugate Market: By Drug, 2020-2030, USD (Million)
11. Company Profile
11.1. Seattle Genetics, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. F. Hoffman-La Roche
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. ImmunoGen, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Novartis AG
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Takeda Pharmaceutical Company Limited
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Immunomedics, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Agensys, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Concortis Biotherapeutics
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. NBE-Therapeutics
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Polytherics (An Abzena Company)
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Oxford BioTherapeutics
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Spirogen (MedImmune)
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. Others
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives
List of Figures
Figure 1 Global Antibody Drug Conjugate Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Antibody Drug Conjugate Market: Quality Assurance
Figure 5 Global Antibody Drug Conjugate Market, By Drug, 2021
Figure 6 Global Antibody Drug Conjugate Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Antibody Drug Conjugate Market, 2021
Figure 8 Market Positioning of Key Antibody Drug Conjugate Market Players, 2021
Figure 9 Global Antibody Drug Conjugate Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Antibody Drug Conjugate Market, By Drug, 2021 Vs 2030, %
Figure 11 U.S. Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 12 Canada Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 14 UK Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 15 Germany Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 16 Spain Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 17 Italy Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 18 France Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 20 China Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 21 Japan Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 22 India Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 23 Australia Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 24 South Korea Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 26 Brazil Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 27 Mexico Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 29 GCC Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 30 Africa Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Antibody Drug Conjugate Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 2 North America Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 3 U.S. Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 4 Canada Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 5 Rest of North America Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 6 UK and European Union Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 7 UK Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 8 Germany Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 9 Spain Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 10 Italy Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 11 France Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 12 Rest of Europe Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 13 Asia Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 14 China Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 15 Japan Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 16 India Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 17 Australia Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 18 South Korea Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 19 Latin America Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 20 Brazil Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 21 Mexico Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 22 Rest of Latin America Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 23 Middle East and Africa Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 24 GCC Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 25 Africa Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Antibody Drug Conjugate Market By Drug, 2020-2030, USD (Million)

Companies Mentioned

  • Seattle Genetics Inc.
  • F. Hoffman-La Roche
  • ImmunoGen Inc.
  • Bayer AG
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Immunomedics Inc.
  • Agensys Inc.
  • Concortis Biotherapeutics
  • NBE-Therapeutics
  • Pfizer
  • Polytherics (An Abzena Company)
  • Oxford BioTherapeutics
  • Spirogen (MedImmune)